Inhibrx Biosciences, Inc. (INBX)
90.53
-4.48
(-4.72%)
USD |
NASDAQ |
Oct 12, 16:00
90.46
-0.07
(-0.08%)
After-Hours: 20:00
Inhibrx Biosciences Total Liabilities (Quarterly) : 207.20M for June 30, 2026
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 207.20M |
| March 31, 2026 | 205.00M |
| December 31, 2025 | 138.48M |
| September 30, 2025 | 140.64M |
| June 30, 2025 | 143.56M |
| March 31, 2025 | 148.20M |
| Date | Value |
|---|---|
| December 31, 2024 | 47.18M |
| September 30, 2024 | 44.10M |
| June 30, 2024 | 39.05M |
| March 31, 2024 | 277.01M |
| December 31, 2023 | 264.39M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Agenus, Inc. | 378.54M |
| Amgen, Inc. | 83.95B |
| Anika Therapeutics, Inc. | 46.19M |
| BioCryst Pharmaceuticals, Inc. | 1.012B |
| Imunon, Inc. | 10.80M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 154.22M |
| Shareholders Equity (Quarterly) | -52.98M |
| Debt to Equity Ratio | -3.428 |
| Current Ratio | 5.067 |
| Net Debt Paydown Yield | -1.08% |